| Mr Christopher Lee Nelson, MD | |
|
42 Business Centre Dr, Suite 308, Miramar Beach, FL 32550-6920 | |
| (850) 460-8778 | |
| (850) 460-8779 |
| Full Name | Mr Christopher Lee Nelson |
|---|---|
| Gender | Male |
| Speciality | Pain Medicine - Interventional Pain Medicine |
| Location | 42 Business Centre Dr, Miramar Beach, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386639474 | NPI | - | NPPES |
| 64065196 | Medicaid | KY | |
| 1329F | Other | NC | BLUE CROSS BLUE SHIELD NORTH CAROLINA |
| 37667 | Other | KY | MEDICAL LICENSE |
| ME 123663 | Other | FL | FL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 37667 (Kentucky) | Primary |
| 207L00000X | Anesthesiology | 200201130 (North Carolina) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Christopher Lee Nelson, MD 10301 Champion Farms Dr, Louisville, KY 40241-6129 Ph: (502) 423-1021 | Mr Christopher Lee Nelson, MD 42 Business Centre Dr, Suite 308, Miramar Beach, FL 32550-6920 Ph: (850) 460-8778 |
News Archive
Technion-Israel Institute of Technology researchers have discovered new mechanisms developed by cancer cells to become resistant to various chemotherapy drugs.
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine - or tailoring treatment for individual people - can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference, today (Friday).
Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
› Verified 6 days ago